<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00726960</url>
  </required_header>
  <id_info>
    <org_study_id>Aprepitant 1</org_study_id>
    <nct_id>NCT00726960</nct_id>
  </id_info>
  <brief_title>Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers</brief_title>
  <official_title>Modulation of Opiate Reward by NK1 Antagonism: A Laboratory-Based Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health and Social Affairs, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>County of Stockholm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine whether aprepitant blocks the opiate reward
      system in non-dependent opiate abusers, indicating its potential as a safe, non-addictive
      first line therapy for early heroin abuse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This initial proof-of-concept study focuses on evaluating whether an NK1 antagonist,
      aprepitant, can block opiate reward in non-dependent opiate experienced volunteers in
      response to a standard opiate challenge. Sixty subjects will be included in a randomized
      controlled study. Following a training challenge session, they will receive 1 week treatment
      with aprepitant or matching placebo, followed by a challenge session during which subjective
      and physiological responses to the opiate partial agonist buprenorphine will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be self-reported pleasurable opiate effect.</measure>
    <time_frame>One week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary outcome will be physiological opiate responses.</measure>
    <time_frame>One week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <condition>Heroin Dependence</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aprepitant</intervention_name>
    <description>Oral, 125 mg once daily for one week</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pseudo-placebo - buprenorphine</intervention_name>
    <description>Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Subutex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 50

          -  Current opiate use, without dependence

        Exclusion Criteria:

          -  Clinical diagnosis of opiate dependence

          -  Positive urine screen for opiates on day of challenge sessions

          -  Meet diagnostic criteria for any other substance abuse disorder except nicotine within
             the last 12 months.

          -  Any ongoing prescription medication other than oral contraceptives or hormone
             replacement

          -  Any serious medical condition which in the judgment of the investigators makes
             administration of opiates medically inappropriate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Heilig, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Universitetssjukhuset</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johan Kakko, MD</last_name>
    <role>Study Director</role>
    <affiliation>Karolinska Universitetssjukhuset</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University Hospital, Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2008</study_first_submitted>
  <study_first_submitted_qc>July 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2008</study_first_posted>
  <last_update_submitted>July 30, 2008</last_update_submitted>
  <last_update_submitted_qc>July 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Markus Heilig, MD, PhD</name_title>
    <organization>Karolinska Universitetssjukhuset</organization>
  </responsible_party>
  <keyword>Heroin abuse</keyword>
  <keyword>Opioids</keyword>
  <keyword>Opiates</keyword>
  <keyword>Substance abuse</keyword>
  <keyword>Addiction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Opiate Alkaloids</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

